Share chart Merck & Co
About
Merck & Co., Inc. действует как медицинская компания по всему миру. Он работает через два сегмента: фармацевтический сегмент и сегмент ветеринарии. Фармацевтический сегмент предлагает фармацевтические продукты для здоровья человека в областях онкологии, неотложной помощи в больницах, иммунологии, неврологии, вирусологии, сердечно-сосудистой системы, диабета и женского здоровья, а также вакцины.
More detailsЦена ао | 116.35 |
---|---|
Дивиденд ап | 0.0228 |
Див.доход ап | 9.78 |
P/E | 22.82 |
P/S | 4.8 |
P/BV | 8.64 |
EV/EBITDA | 18.74 |
Дивиденд ао | 2.92 |
Див.доход ао | 2.68 |
EBITDA | 12.88 |
Сайт | http://www.merck.com |
Число акций ао | 2.547 млрд |
Выручка | 46.84 |
ISIN | US58933Y1055 |
Change price per day: | -1.8804% (118.59) |
---|---|
Change price per week: | +0.2844% (116.03) |
Change price per month: | -8.94% (127.78) |
Change price per 3 month: | -7.58% (125.9) |
Change price per half year: | -8.49% (127.15) |
Change price per year: | +5.69% (110.1) |
Change price per 3 year: | +46.99% (79.16) |
Change price per 5 year: | +47.16% (79.0716) |
Change price per year to date: | +10.44% (105.36) |
All parameters ⇨
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Dividends, % | Dividends | Result of period | Buy before | Register closing date | Payment before |
---|---|---|---|---|---|
0.6% | 0.77 | I кв. 2024 | 14.06.2024 | 17.06.2024 | 02.07.2024 |
0.59% | 0.77 | IV кв. 2023 | 12.03.2024 | 14.03.2024 | 29.03.2024 |
0.66% | 0.73 | II кв. 2023 | 12.09.2023 | 14.09.2023 | 29.09.2023 |
0.66% | 0.73 | I кв. 2023 | 12.06.2023 | 14.06.2023 | 29.06.2023 |
0.67% | 0.73 | IV кв. 2022 | 10.03.2023 | 14.03.2023 | 29.03.2023 |
0.76% | 0.69 | II кв. 2022 | 12.09.2022 | 14.09.2022 | 29.09.2022 |
0.75% | 0.69 | I кв. 2022 | 10.06.2022 | 14.06.2022 | 29.06.2022 |
0.88% | 0.69 | IV кв. 2021 | 11.03.2022 | 14.03.2022 | 29.03.2022 |
0.85% | 0.69 | III кв. 2021 | 10.12.2021 | 14.12.2021 | 29.12.2021 |
0.82% | 0.65 | II кв. 2021 | 10.09.2021 | 14.09.2021 | 29.09.2021 |
0.83% | 0.64 | I кв. 2021 | 11.06.2021 | 14.06.2021 | 29.06.2021 |
0.81% | 0.64 | IV кв. 2020 | 10.03.2021 | 12.03.2021 | 29.03.2021 |
Date | Event | |
---|---|---|
13.09.2024 | MRK: последний день с дивидендом $0.77 |
Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
---|---|---|---|---|---|---|---|---|---|
04.05.2024 | 06.05.2024 | Oosthuizen Johannes Jacobus President, U.S. Market |
Purchase | 127.51 | 116 289 | 912 | 0 | 0 | link |
04.05.2024 | 06.05.2024 | Klobuchar Michael A EVP - Chief Strategy Officer |
Purchase | 127.51 | 113 101 | 887 | 0 | 0 | link |
04.05.2024 | 06.05.2024 | DeLuca Richard R. EVP&Pres, Merck Animal Heallth |
Purchase | 127.51 | 3 458 840 | 27126 | 0 | 0 | link |
11.03.2024 | 11.03.2024 | Merck & Co., Inc. 10% Owner |
Purchase | 23 | 492 136 000 | 21397205 | 0 | 0.85 | link |
14.02.2024 | 15.02.2024 | Davis Robert M Chairman, CEO & President |
Sale | 125.4 | 10 661 600 | 85021 | 0 | 0 | link |
14.02.2024 | 15.02.2024 | Davis Robert M Chairman, CEO & President |
Purchase | 73.73 | 6 268 600 | 85021 | 0 | 0 | link |
13.02.2024 | 15.02.2024 | Davis Robert M Chairman, CEO & President |
Sale | 125.85 | 18 877 500 | 150000 | 0 | -0.01 | link |
13.02.2024 | 15.02.2024 | Davis Robert M Chairman, CEO & President |
Purchase | 74.18 | 11 127 000 | 150000 | 0 | 0.01 | link |
28.04.2023 | 28.04.2023 | Davis Robert M Chairman, CEO & President |
Sale | 114.93 | 16 472 800 | 143329 | 0 | -0.01 | link |
28.04.2023 | 28.04.2023 | Davis Robert M Chairman, CEO & President |
Purchase | 56.04 | 8 032 160 | 143329 | 0 | 0.01 | link |
Institutions | Volume | Share, % |
---|---|---|
Vanguard Group Inc | 244776747 | 9.66 |
Blackrock Inc. | 201836434 | 7.97 |
State Street Corporation | 116865977 | 4.61 |
Wellington Management Group, LLP | 85595999 | 3.38 |
Geode Capital Management, LLC | 55428245 | 2.19 |
FMR, LLC | 42800017 | 1.69 |
Morgan Stanley | 40129825 | 1.58 |
Bank of America Corporation | 37994581 | 1.5 |
Charles Schwab Investment Management, Inc. | 36682866 | 1.45 |
Price (T.Rowe) Associates Inc | 30087217 | 1.19 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Ms. Jennifer L. Zachary | Executive VP & General Counsel | 2.73M | 1979 (45 years) |
Ms. Caroline Litchfield | Executive VP & CFO | 2.8M | 1969 (55 years) |
Mr. David Michael Williams | Executive VP and Chief Information & Digital Officer | N/A | 1969 (55 years) |
Mr. Robert M. Davis J.D. | Chairman, President & CEO | 6.08M | 1967 (57 years) |
Mr. Peter Dannenbaum | Vice President of Investor Relations | N/A | |
Lisa LeCointe-Cephas | Senior VP and Chief Ethics & Compliance Officer | N/A | 1982 (42 years) |
Dr. Dean Y. Li M.D., Ph.D. | Executive VP & President of Merck Research Laboratories | 3.44M | 1962 (62 years) |
Ms. Cristal N. Downing | Executive VP and Chief Communications & Public Affairs Officer | N/A | 1969 (55 years) |
Mr. Chirfi Guindo | Senior VP & Chief Marketing Officer of Human Health | 1.54M | 1966 (58 years) |
Mr. Dalton E. Smart III | Senior VP of Finance, Principal Accounting Officer & Global Controller | N/A | 1967 (57 years) |
Address: United States, Kenilworth, NJ , 2000 Galloping Hill Road - open in Google maps, open in Yandex maps
Website: http://www.merck.com
Website: http://www.merck.com